5-HT3 receptors antagonists reduce serotonin-induced scratching in mice

Fundamental and Clinical Pharmacology

Volumn 29, Issue 3, 2015, Pages 310-315

  Ostadhadi, Sattar ^a,b   Kordjazy, Nastaran ^a,b   Haj Mirzaian, Arya ^a,b   Mansouri, Parvin ^c   Dehpour, Ahmad Reza ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 HT3 antagonists; Mice; Scratching; Serotonin (5 HT)

Indexed keywords

ONDANSETRON; SEROTONIN 3 RECEPTOR; TROPISETRON; ANTIPRURITIC AGENT; INDOLE DERIVATIVE; SEROTONIN; SEROTONIN 3 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCRATCHING; SKIN PRURITUS; TREATMENT OUTCOME; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PRURITUS; PSYCHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPRURITICS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MICE; ONDANSETRON; PRURITUS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 84929292074     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12112     Document Type: Article

References (33)

1. Ikoma A., Steinhoff M., Ständer S., Yosipovitch G., Schmelz M. The neurobiology of itch. Nat. Rev. Neurosci. (2006) 7 535-547.
2. Steinhoff M., Bienenstock J., Schmelz M., Maurer M. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J. Invest. Dermatol. (2006) 126 1705-1718.
3. Greaves M.W. Itch in systemic disease: therapeutic options. Dermatol. Ther. (2005) 18 323-327.
4. Weisshaar E., Apfelbacher C., Jäger G. et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br. J. Dermatol. (2006) 155 957-964.
5. Twycross R., Greaves M., Handwerker H. et al. Itch: scratching more than the surface. QJM (2003) 96 7-26.
6. 2 receptors in mice. Neurosci. Res. (1999) 35 77-83.
7. Weisshaar E., Ziethen B., Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm. Res. (1997) 46 412-416.
8. Fitzsimons E., Dagg J., McAllister E. Pruritus of polycythaemia vera: a place for pizotifen? BMJ (Clin. Res. Ed.) (1981) 283 277.
9. 3) receptor antagonists: effectiveness of ondansetron. Pain (1995) 61 33-37.
10. Ashmore S.D., Jones C.H., Newstead C.G., Daly M.J., Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am. J. Kidney Dis. (2000) 35 827-831.
11. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. (2002) 71 533-554.
12. Nojima H., Carstens E. 5-Hydroxytryptamine (5-HT) 2 receptor involvement in acute 5-HT-evoked scratching but not in allergic pruritus induced by dinitrofluorobenzene in rats. J. Pharmacol. Exp. Ther. (2003) 306 245-252.
13. Schwörer H., Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet (1993) 341 1277.
14. Layegh P., Mojahedi M.J., Malekshah P. et al. Effect of oral granisetron in uremic pruritus. Indian J. Dermatol. Venereol. Leprol. (2007) 73 231.
15. Raderer M., Muller C., Scheithauer W. Ondansetron for pruritus due to cholestasis. N. Engl. J. Med. (1994) 330 1540.
16. Charuluxananan S., Somboonviboon W., Kyokong O., Nimcharoendee K. Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Reg. Anesth. Pain Med. (2000) 25 535-539.
17. Balaskas E.V., Bamihas G.I., Karamouzis M., Voyiatzis G., Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron (1998) 78 395-402.
18. Figueiredo A., Ribeiro C.A., Goncalo M., Almeida J., Poiares-Baptista A., Teixeira F. Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam. Clin. Pharmacol. (1990) 4 147-158.
19. Goineau S., Guillaume P., Barrais L., Castagné V. Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron. Fundam. Clin. Pharmacol. (2014) 28 643-651.
20. Rajkumar R., Mahesh R. Review: the auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J. Psychopharmacol. (2010) 24 455-469.
21. Thomsen J.S., Petersen M., Benfeldt E., Jensen S., Serup J. Scratch induction in the rat by intradermal serotonin: a model for pruritus. Acta Derm. Venereol. (2001) 81 250-254.
22. Kini S.P., DeLong L.K., Veledar E., McKenzie-Brown A.M., Schaufele M., Chen S.C. The impact of pruritus on quality of life: the skin equivalent of pain. Arch. Dermatol. (2011) 147 1153-1156.
23. Nakagawa H., Hiura A. Four possible itching pathways related to the TRPV1 channel, histamine, PAR-2 and serotonin. Malays. J. Med. Sci. (2013) 20 5.
24. Hägermark O. Itch mediators. Semin. Dermatol. (1995) 14 271-276.
25. Purcell W., Cohen D., Hanahoe T. Comparison of histamine and 5-hydroxytryptamine content and secretion in rat mast cells isolated from different anatomical locations. Int. Arch. Allergy Immunol. (1989) 90 382-386.
26. Weisshaar E., Ziethen B., Röhl F.W., Gollnick H. The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion-an experimental study. Exp. Dermatol. (1999) 8 254-260.
27. Schwörer H., Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin. Invest. (1993) 71 659-662.
28. Kyriakides K., Hussain S., Hobbs G. Management of opioid-induced pruritus: a role for 5-HT3 antagonists? Br. J. Anaesth. (1999) 82 439-441.
29. Aapro M.S. 5-HT3 receptor antagonists. Drugs (1991) 42 551-568.
30. Fozard JR. The development and early clinical evaluation of selective 5-HT3 receptor antagonists, in: Fozard J (ed) The peripheral actions of 5-hydroxytryptamine. Oxford University Press, Oxford, UK. 1995, pp. 354-376.
31. Richardson B., Engel G., Donatsch P., Stadler P. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature (1984) 316 126-131.
32. Saynor D., Dixon C. The metabolism of ondansetron. Eur. J. Cancer Clin. Oncol. (1988) 25 S75-S77.
33. Yang S.H., Lee M.G. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. Biopharm. Drug Dispos. (2008) 29 414-426.